Literature DB >> 32356282

Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer.

Manuel Zorzi1, Cesare Hassan2, Giulia Capodaglio3, Maddalena Baracco1, Giulio Antonelli2, Emanuela Bovo1, Massimo Rugge1.   

Abstract

BACKGROUND : Colorectal cancer (CRC) screening programs based on fecal immunochemical testing (FIT) generate substantial pressure on colonoscopy capacity in Europe. Thus, a relevant proportion of FIT-positive patients undergo colonoscopy after the recommended 30-day interval, which may be associated with an excess CRC risk. METHODS : In a cohort of 50-69-year-old patients undergoing biennial rounds of FIT (OC-Hemodia latex agglutination test; cutoff 20 µg hemoglobin/g feces) between 2004 and 2017, we assessed the outcome at colonoscopy (low/high risk adenoma/CRC/advanced stage CRC) among FIT-positive patients, according to different time intervals. The association of each outcome with waiting time, and demographic and clinical factors, was analyzed through multivariable analysis. RESULTS : 123 138/154 213 FIT-positive patients (79.8 %) underwent post-FIT colonoscopy. Time to colonoscopy was ≤ 30 days, 31-180 days, and ≥ 181 days in 50 406 (40.9 %), 71 724 (58.3 %), and 1008 (0.8 %) patients, respectively. At colonoscopy, CRC, high risk adenoma, and low risk adenoma were diagnosed in 4813 (3.9 %), 30 500 (24.8 %), and 22 986 (18.7 %) patients, respectively. An increased CRC prevalence at colonoscopy was observed for a time to colonoscopy of ≥ 270 days (odds ratio [OR] 1.75, 95 % confidence interval [CI] 1.15-2.67), whereas it was stable for waiting times of < 180 days. The proportion of advanced CRC also increased after 270 days (OR 2.79, 95 %CI 1.03-7.57). No increase for low or high risk adenomas according to time to colonoscopy was observed. CONCLUSION : In a European FIT-based screening program, post-FIT colonoscopy after 9 months was associated with an increased risk of CRC and CRC progression. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32356282     DOI: 10.1055/a-1159-0644

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  8 in total

1.  Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality.

Authors:  Yazmin San Miguel; Joshua Demb; Maria Elena Martinez; Samir Gupta; Folasade P May
Journal:  Gastroenterology       Date:  2021-02-02       Impact factor: 22.682

2.  Resuming endoscopy during COVID-19 pandemic: ESGE, WEO and WGO Joint Cascade Guideline for Resource Limited Settings.

Authors:  Giulio Antonelli; John Gasdal Karsensten; Purnima Bhat; Uchenna Ijoma; Chukwuemeka Osuagwu; Hailemichael Desalegn; Hanna Abera; Claire Guy; Peter Vilmann; Mario Dinis-Ribeiro; Thierry Ponchon; Luis Carlos Sabbagh; Nonthalee Pausawasdi; Govind Makharia; Cesare Hassan; Andrew Veitch; Lars Aabakken; Alanna Ebigbo
Journal:  Endosc Int Open       Date:  2021-03-17

3.  Risk for Colorectal Cancer in Patients with Serially Positive Fecal Immunochemistry Test in an Annual Screening Program.

Authors:  Takuji Kawamura; Kana Amamiya; Naonori Inoue; Naokuni Sakiyama; Yusuke Okada; Kasumi Sanada; Mai Kamaguchi; Kenichi Nishioji; Kiyohito Tanaka; Koji Uno; Kenjiro Yasuda
Journal:  J Anus Rectum Colon       Date:  2021-10-28

4.  The impact of the COVID-19 pandemic on colorectal and gastric cancer diagnosis, disease stage and mortality.

Authors:  Naim Abu-Freha; Reut Hizkiya; Muhammad Abu-Abed; Tal Michael; Binil Mathew Jacob; Keren Rouvinov; Doron Schwartz; Avraham Reshef; Uri Netz; Ilia Pinsk; Ohad Etzion
Journal:  Front Med (Lausanne)       Date:  2022-09-26

5.  Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality.

Authors:  Luigi Ricciardiello; Clarissa Ferrari; Michela Cameletti; Federica Gaianill; Francesco Buttitta; Franco Bazzoli; Gian Luigi de'Angelis; Alberto Malesci; Luigi Laghi
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-06       Impact factor: 11.382

Review 6.  What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective.

Authors:  Marco Spadaccini; Lorenzo Canziani; Alessio Aghemo; Ana Lleo; Roberta Maselli; Andrea Anderloni; Silvia Carrara; Alessandro Fugazza; Gaia Pellegatta; Piera Alessia Galtieri; Cesare Hassan; David Greenwald; Mark Pochapin; Michael Wallace; Prateek Sharma; Thomas Roesch; Pradeep Bhandari; Fabian Emura; Gottumukkala S Raju; Alessandro Repici
Journal:  United European Gastroenterol J       Date:  2021-06-08       Impact factor: 6.866

7.  Mitigating the impact of COVID-19 on colorectal cancer screening: Organized service screening perspectives from the Asia-Pacific region.

Authors:  Han-Mo Chiu; Chiu-Wen Su; Weng-Feng Hsu; Grace Hsiao-Hsuan Jen; Chen-Yang Hsu; Sam Li-Sheng Chen; Hsiu-Hsi Chen
Journal:  Prev Med       Date:  2021-05-25       Impact factor: 4.637

8.  Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.

Authors:  Manuel Zorzi; Jessica Battagello; Kevin Selby; Giulia Capodaglio; Susanna Baracco; Silvia Rizzato; Enrico Chinellato; Stefano Guzzinati; Massimo Rugge
Journal:  Gut       Date:  2021-03-31       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.